Intravenous milrinone for treatment of delayed cerebral ischaemia following subarachnoid haemorrhage: a pooled systematic review

2021 ◽  
Author(s):  
Mendel Castle-Kirszbaum ◽  
Leon Lai ◽  
Julian Maingard ◽  
Hamed Asadi ◽  
R. Andrew Danks ◽  
...  
Keyword(s):  
Systematic Review ◽  
Subarachnoid Haemorrhage ◽  
Cerebral Ischaemia ◽  
Delayed Cerebral Ischaemia

Nimodipine for delayed cerebral ischaemia after subarachnoid haemorrhage

1992 ◽  
Vol 30 (21) ◽  
pp. 81-83 ◽  
Keyword(s):  
Calcium Antagonist ◽  
Cerebral Infarction ◽  
Subarachnoid Haemorrhage ◽  
Cerebral Ischaemia ◽  
Neurological Outcome ◽  
Initial Phase ◽  
Morbidity And Mortality ◽  
Delayed Cerebral Ischaemia

Subarachnoid haemorrhage (SAH) occurs in about one in every 1000 adults.1 Left untreated, around one third of people with an SAH die within 3 days of the initial bleed. Of those who survive the initial phase many go on to develop ‘delayed’ cerebral ischaemia, which itself is associated with cerebral infarction and an increase in morbidity and mortality. The calcium antagonist nimodipine (Nimotop – Bayer) is promoted as a drug that “reduces cerebral infarction and improves neurological outcome in SAH”. How effective is it?

Delayed cerebral ischaemia in patients with aneurysmal subarachnoid haemorrhage: Functional outcome and long‐term mortality

2019 ◽  
Vol 63 (9) ◽  
pp. 1191-1199 ◽  
Author(s):  
Markus Harboe Olsen ◽  
Matias Orre ◽  
Anna Cold Winge Leisner ◽  
Rune Rasmussen ◽  
Søren Bache ◽  
...  
Keyword(s):  
Subarachnoid Haemorrhage ◽  
Functional Outcome ◽  
Cerebral Ischaemia ◽  
Aneurysmal Subarachnoid Haemorrhage ◽  
Delayed Cerebral Ischaemia ◽  
Long Term Mortality
Sign in / Sign up

Export Citation Format

Share Document